MANNIN RESEARCH TO PARTICIPATE AT ARVO 2016 MEETING

New York,  April 4,2016- Q BioMed Inc. (QBIO), a biotechnology acceleration company announces that its technology partner Mannin Research Inc. will be attending the Association for Research in Vision and Ophthalmology (ARVO), which takes place from May 1-5, 2016 in Seattle Washington. Mannin Research executives will be meeting with its vendors and research partners. The […]

Read More

Q BioMed Inc. To Present at the Global Chinese Financial Forum on April 30, 2016

Toronto, ON Conference Expects to attract over 200 participants New York, NY– (April 26, 2016)– Q BioMed Inc. (OTCQB: QBIO) a biotechnology acceleration company, today announced that the company will present at the Global Chinese Financial Forum (GCFF). The GCFF is the most prominent series of bi-lingual financial functions in both North America and China. […]

Read More

MANNIN RESEARCH TO PRESENT GLAUCOMA THERAPEUTICS TREATMENT AT MEDCITY INVEST CHICAGO APRIL 12 -13 2016

Management to Present Lead drug candidate to Industry and Venture Finance Executives NEW YORK, April 12, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce that its  license technology partner,  Mannin Research, will present at  MATTER Midwest University HealthTech Showcase on April 12 – 13th, 2016. Mannin Research will […]

Read More

Media Alert – Q BioMed Inc Featured in April issue of PharmaVOICE Magazine

Getting Past the “Pharma Bro”; How Smaller Biotechs Continue to Strive for the Well-Being of Patients   New York,  April 5 ,2016  – Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company reports the Company’s CEO  was featured in  an interview in the April issue of PharmaVOICE magazine. PharmaVOICE magazine, reaching more  than 41,000 BPA-qualified life-sciences […]

Read More

StockNewsNow.com Publishes New SNNLive Video Interview With Q BioMed Inc.

LOS ANGELES, CA–(Marketwired – March 24, 2016) –  StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Denis Corin, Chairman and CEO of Q BioMed Inc. (OTCQB: QBIO), a biomedical acceleration and development company, according to the Company’s website (see here: www.QBioMed.com). The video interview was recorded on Monday, February 22nd, […]

Read More

President of Q BioMed Inc. Expands on Corporate Update in Q&A

Denis Corin Discusses Mannin Research Inc’s Leading Glaucoma Drug Candidate MAN-01   POINT ROBERTS, WA–(Marketwired – March 21, 2016) –  Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases a recent interview with Mr. Denis Corin, President of Q BioMed Inc. (OTCQB: QBIO). Denis expands on the recent corporate […]

Read More

Q BIOMED INC. CONGRATULATES MANNIN RESEARCH ON SELECTION TO THE CHICAGO-CANADA MENTORSHIP PROGRAM (C2MP) AND INAUGURAL MEETING

Mannin assigned world class industry mentors and advisors NEW YORK, March 17, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to congratulate Mannin Research on its selection to the C2MP program and the exceptional mentors and advisors now included in the long list of industry experts available to assist in […]

Read More

Q BioMed Inc. To Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016

New York, NY– (February 16, 2016)– Q BioMed Inc. (OTCQB: QBIO) a biotechnology acceleration company, today announced that the company will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at The Ritz-Carlton in Miami on South Beach on February 22, 2016.  Please click here for a list of presenting companies. […]

Read More

Q BIOMED INC. PROVIDES A CORPORATE UPDATE

Company Closes $1,000,000 in Notes and Securities Purchase Agreements     NEW YORK, February 4, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to provide the following update on recent corporate developments. Over the last 3 months we have significantly increased our cash position through several convertible note and securities […]

Read More
Social media & sharing icons powered by UltimatelySocial